Jenscare Scientific Co. Ltd. has announced promising results from its recent studies on two innovative medical devices. The 30-day follow-up results from the global multicenter clinical trial of the LuX-Valve Plus transcatheter tricuspid valve replacement, known as the TRINITY study, as well as the one-year follow-up data from the JensClip transcatheter mitral valve repair system, were unveiled at EuroPCR 2025 in Paris. The findings indicate that 96.3% of patients experienced no regurgitation above moderate levels. Additionally, improvements were noted in various indicators such as the New York Heart Association cardiac function, Kansas City Cardiomyopathy Questionnaire scores, and six-minute walking distance. Jenscare Scientific aims to continue advancing the application and commercialization of these products globally, although it cautions that there is no guarantee of ultimate success in development and marketability.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.